SHP1
Shp1; PTPN6; Src homology region 2 (SH-2) domain-containing phosphatase 1
SHP1 is a protein tyrosine phosphatase (PTP) that plays a crucial role in regulating various signaling pathways, particularly in hematopoietic cells and the immune system. This is particularly apparent in motheaten (me) mice that have a spontaneous mutation in Ptpn6, resulting in loss of SHP1, and develop a broad array of inflammatory and autoimmune symptoms.
All Product Categories
-
SHP1 Related Products (25)
Related Products (25)
- 1
- 2
-
SC-60
0 ImagesCat. No.: HY-W717425CAS No.: 1421677-31-7SC-60 is a derivative of Sorafenib (HY-10201). SC-60 exerts its anti-tumor effect by activating the phosphatase activity of SHP-1, thereby inhibiting the STAT3 signaling pathway. SC-60 exhibits strong proliferation inhibitory activity in various hepatocellular carcinoma (HCC) cell lines. SC-60 downregulates the expression of downstream anti-apoptotic proteins (such as Bcl-2, Cyclin D1, Survivin), ultimately inducing caspase-dependent apoptosis. SC-60 significantly inhibits tumor growth in xenograft tumor models. SC-60 can be used for the study of HCC.
-
Cryptosporioptide A
0 ImagesCat. No.: HY-N12177CAS No.: 1647101-05-0Cryptosporioptide A (Compound 3) is a pigment protein tyrosine phosphatase inhibitor derived from the insect-parasitic fungus Cordyceps gracilioides. Cryptosporioptide A inhibits PTP1B, SHP2, CDC25B, LAR and SHP1 enzymes with IC50 of 7.3, 5.7, 7.6, >50, 4.9 μg/mL, respectively.
-
SHP1-IN-1
0 ImagesCat. No.: HY-D2204CAS No.: 2956720-62-8SHP1-IN-1 (compound 5p) is a fluorescent probe for the protein tyrosine phosphatase SHP1 containing the Src homology 2 domain. SHP1-IN-1 has SHP1 inhibitory activity, selectivity for Fe3+ ions and good fluorescence properties. SHP1-IN-1 exhibits aggregation post-quenching (ACQ) effect, good interference immunity and low detection limit (5.55 μM).
-
SHP1-IN-2
0 ImagesCat. No.: HY-186140SHP1‑IN‑2 is a selective and orally active SHP1 inhibitor. SHP1‑IN‑2 covalently binds to Cys480 of SHP1. SHP1‑IN‑2 elicits potent antitumor immunity and suppresses syngeneic tumor growth. SHP1‑IN‑2 blocks tumor progression in a svngeneic cancer model by activating natural killer cells and cytotoxic CD8＋ T cells, along with reduced T cel l. SHP1‑IN‑2 can be used for cancer‑related research.
-
OSE-279
0 ImagesCat. No.: HY-P992434OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1 ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma.
- 1
- 2
